NetworkNewsBreaks Archive - Page 2181 of 2221

ThursdayJan 19, 2017 11:51 am

NetworkNewsBreaks – Sphere 3D (NASDAQ: ANY) Inks Deal to Acquire HVE and Unified ConneXions; Shares Higher

Shares of Sphere 3D (NASDAQ: ANY) are up 28% after the data management company said it will acquire HVE (Hybrid Virtualization Engine) ConneXions and its sister company, Unified ConneXions, Inc., which achieved combined virtualization revenue of more than $7 million for calendar year 2016. The acquired companies’ products, technologies and professional services will expand Sphere 3D’s virtualization practice and increase its ability to accelerate the delivery of hybrid cloud solutions. The acquisition is anticipated to close before January 31, 2017, and is expected to be accretive in the first quarter of 2017. “UCX has exceptional leadership teams, innovative technology, industry…

ThursdayJan 19, 2017 11:48 am

NetworkNewsBreaks – Rosetta Genomics Ltd. (NASDAQ: ROSG) Sets Stage for Value Creation in 2017

Rosetta Genomics (NASDAQ: ROSG) is an international company leveraging a growing IP portfolio to develop and commercialize microRNA-based and other molecular diagnostic programs in cancer and various other indications. In 2016, Rosetta was primarily focused on the commercial launch of its Reveal assay for the classification of indeterminate thyroid nodules, and it signed an exclusive distribution agreement with Rhenium Ltd. for the sales and marketing of Reveal in Israel. In a December earnings release, Rosetta Genomics said it expects FY2017 RosettaGX Reveal revenue to be between $4 million and $5 million. The company is also advancing a number of other…

WednesdayJan 18, 2017 2:23 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on January 18, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: VPRB 18.09% – News: Presenting at 2017 Big Industry Show in Los Angeles on January 19-20th NXTD 16.48% – News: Posts preliminary results for the year and quarter ended December 31, 2016 UNXL 11.90% – News: Announces preferred equity financing for $3M; Enters into MOU with GIS HPCQ 12.26% – News: Adds Myco BioBoost to product line ESEA 7.83%– News: Announces delivery of Newbuilding Ultramax Drybulk Carrier STLT 7.25% – News: Subsidiary Caretta Therapeutics…

WednesdayJan 18, 2017 2:19 pm

NetworkNewsBreaks – BiondVax Pharmaceuticals’ (NASDAQ: BVXV) Flu Vaccine Candidate Shows Potential to Cover Mutating Strains

One of the primary concerns of conventional vaccination is historically low efficacy. BiondVax (NASDAQ: BVXV), which earlier this month received an investment of $2.8 million to continue its development, is focused on creating a universal flu vaccine that would provide effective, multi-season protection. The company’s M-001 vaccine was recently featured in peer-reviewed scientific journal Vaccine, which reports that M-001 administered in the 2011 flu season significantly increased protective antibodies against the strain (A/Swiss) that caused the 2014/2015 influenza epidemic. Notably, the A/Swiss strain did not exist when M-001 was administered several years before. The results demonstrate M-001’s ability to provide…

WednesdayJan 18, 2017 1:25 pm

NetworkNewsBreaks – aTyr’s (NASDAQ: LIFE) Resolaris™ Obtains Fast Track Designation from FDA, Partial Clinical Hold Removed

Shares of aTyr Pharma (NASDAQ: LIFE) climbed more than 25% in mid-day trade following news that the company’s Resolaris™ candidate was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of limb girdle muscular dystrophy 2B, making it the first known therapeutic candidate to receive the designation for this treatment. The FDA also removed its partial clinical hold on a dosing ceiling for Resolaris in clinical trials, providing dosing flexibility moving forward. "This Fast Track designation, which is granted to drug candidates addressing serious conditions and that demonstrate the potential to address unmet medical…

WednesdayJan 18, 2017 1:21 pm

NetworkNewsBreaks – Apricus Biosciences (NASDAQ: APRI) Shares Skyrocket on Approval of Vitaros® in Mexico

Shares of Apricus Biosciences (NASDAQ: APRI) soared more than 153% after the company announced that Mexico has granted Apricus’ commercialization partner, Ferring Pharmaceuticals, market approval for Vitaros®, an on-demand topical cream for erectile dysfunction. Per an agreement between the two companies, Apricus has received a total of $4.5 million in upfront payments from Ferring, in addition to a regulatory milestone payment of $1.6 million. Apricus is eligible to receive up to an additional $28 million in regulatory, launch and sales milestones, plus royalties on future net sales. Ferring is anticipated to launch in Mexico and Argentina during the second quarter…

WednesdayJan 18, 2017 10:45 am

NetworkNewsBreaks – Aegis Reiterates ‘Buy’ Rating for Xtant Medical Holdings, Inc. (NYSE: XTNT) following 2016 Preliminary Results, Guidance for 2017

Noting two quarters of double-digit growth, Aegis Capital has reiterated its 'Buy' rating and $3.50 price target for Xtant Medical (NYSE MKT: XTNT). Xtant Friday reported preliminary fourth quarter 2016 revenues of at least $24.5 million, an increase of 10% compared to the year ago quarter, and in line with Aegis estimates of $24.6 million. Adjusted EBITDA for the fourth quarter is expected to be at least $1.25 million vs a loss of $350,000 in the fourth quarter of 2015, shy of Aegis’ estimates of $1.5 million. Xtant estimates full-year 2016 revenue of at least $90 million, up 4.1% compared…

TuesdayJan 17, 2017 3:50 pm

NetworkNewsBreaks – Veru Healthcare (NASDAQ: FHCO) Continues Rally on Launch of OTC Premature Ejaculation Product

Shares of Veru Healthcare (NASDAQ: FHCO) are higher in Monday trade, moving on momentum from the recent launch of the company's proprietary, over-the-counter PREBOOST® product to help prevent premature ejaculation (PE). As the only individually packaged medicated wipe that contains a desensitizing agent (4% benzocaine), PREBOOST allows for discrete, direct and precise dosage with each use. Top line results from an independent clinical study of PREBOOST show that men treated with PREBOOST had statistically significant improvement in their ability to control ejaculation, while 80% were no longer considered to have PE. The intended reach of PREBOOST is two-fold. On one…

TuesdayJan 17, 2017 2:46 pm

NetworkNewsBreaks – Alcobra (NASDAQ: ADHD) Shares Plunge on Disappointing Results of MDX Clinical Trial

Shares of Alcobra (NASDAQ: ADHD) slumped 49% today after the company reported top-line results from MEASURE, its second phase 3 clinical trial for the investigational product Metadoxine Extended Release (MDX) for the treatment of ADHD in adult patients. MDX did not meet the primary endpoint of demonstrating a statistically significant difference from placebo in the change from baseline of the investigator rating of the Conners’ Adult ADHD Rating Scales (CAARS). "We are exceedingly disappointed with these top-line results. In the coming weeks, the Company intends to review the full data set from MEASURE. Consequently, we will evaluate our options and…

TuesdayJan 17, 2017 2:05 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on January 17, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: PULM 135.33% – News: PUR1900 obtains Qualified Infectious Disease Product designation by FDA OWCP 53.08% – News: Releases annual shareholders letter REXX 27.42% – News: Releases two-year financial and operational plan; provides financial update ITRO 25.19% – News: Ships first silver bullion produced by its e-scrap refining technology HTCO 23.33% – News: Introduces GrowLease: lease programs for its flagship of automated grow systems PME 13.67% – News: Declares Q1 2017 quarterly cash dividend CGIX…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks